Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial.

ALTAIR (NCT04457297) randomized 243 ctDNA-positive people without radiographic disease to trifluridine/tipiracil or placebo. Median disease-free survival was 9.30 versus 5.55 months (HR 0.79, P = 0.107). The primary endpoint was not met.

Nature MedicinePubMed 42260101DOI 10.1038/s41591-026-04428-0